Canada has granted approval for the first generic versions of Ozempic, a widely used diabetes medication, developed by Dr. Reddy's Laboratories. This significant milestone comes after the expiration of patent protections for semaglutide, the drug's active ingredient, in January 2023. The approval is expected to lead to a price war, as generic medicines in Canada are typically priced 45% to 90% lower than their branded counterparts. With the entry of generics, monthly treatment costs could drop to as low as $14 in certain markets. The approval also follows a trend initiated earlier this year when India launched its own generic versions of semaglutide, prompting Novo Nordisk, the original developer, to reduce prices for Ozempic and Wegovy. As Health Canada evaluates additional applications for generic semaglutide, the market is poised for increased competition, benefiting patients but potentially squeezing profit margins for manufacturers.